Newsfeeds - Spark Newswire

1 minute read

ChampionX Q4 EPS $0.43 Beats $0.41 Estimate, Sales $985.86M Miss $1.01B Estimate

Today, 5:49 AM

ChampionX (NASDAQ:CHX) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.41 by 4.88 percent. This is a 65.38 percent increase over earnings of $0.26 per share from the same

CHX

1 minute read

Citigroup Maintains Buy on ChampionX, Raises Price Target to $34

By Benzinga Newsdesk

Today, 5:49 AM

Citigroup analyst Scott Gruber maintains ChampionX (NASDAQ:CHX) with a Buy and raises the price target from $30 to $34.

CHX

5 minute read

Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:49 AM

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat.

$APE

2 minute read

Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday

By Lisa Levin

Today, 5:49 AM

U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session.

AGYS

14 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 6, 2022

By Benzinga Insights

Today, 5:49 AM

Upgrades

ACRS

1 minute read

Barclays Downgrades ChampionX to Equal-Weight, Lowers Price Target to $28

By Benzinga Newsdesk

Today, 5:49 AM

Barclays analyst David Anderson downgrades ChampionX (NASDAQ:CHX) from Overweight to Equal-Weight and lowers the price target from $38 to $28.

CHX

2 minute read

News

ChampionX’s Subsidiary US Synthetic Considering Challenge To Patent Ruling But Expects It To Have Limited Impact On Financial Results

By Benzinga Newsdesk

Today, 5:49 AM

US Synthetic Corporation, a subsidiary of ChampionX Corporation ("ChampionX" or the "Company") (NASDAQ:CHX), announced today that it is considering options, including a possible appeal, in response to

CHX

2 minute read

Is 2023 The ‘Trickle-Down Year’ For NOV? Why This Wall Street Analyst Is Bullish

By Robert Kuczmarski

Today, 5:49 AM

Bank Of America analyst Chase Mulvehill upgraded NOV (NYSE: NOV) with a price target of $19. Key Takeaways: "Trickle-down on the move; upgrade to Buy," Mulvehill said in a note.

CHX